Ignite Creation Date:
2024-05-05 @ 4:44 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00306514
Status:
COMPLETED
Last Update Posted:
2007-09-20
First Post:
2006-03-23
Brief Title:
Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients
Sponsor:
Cytos Biotechnology AG
Organization:
Cytos Biotechnology AG
Study Overview
Official Title:
A Phase IIa Study to Evaluate Safety Tolerability and Immunogenicity of a Melan-A VLP Vaccine in HLA-A2 Positive Patients With Stage IIIIV Malignant Melanoma
Status:
COMPLETED
Status Verified Date:
2007-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate whether vaccination with a Melan-A VLP vaccine leads to a specific cellular immune response in patients with malignant melanoma at advanced stage of the disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None